Health industries

  • MoneyTreeTM venture capital funding: Capital crunch

    5/22/13 | Pharmaceuticals & life science

    The life sciences share of total venture funding declined from 28% during the last quarter of 2012 to 23% during the first quarter of 2013. Biotechnology, raising $875 million in 96 deals during the first quarter, placed a distant second in dollars raised behind software, which drew $2.3 billion in 329 deals.

  • Pharmaceutical and Life Sciences Deals Insights Quarterly

    5/20/13 | Transaction services

    Merger and acquisition deal value in the pharmaceutical and life sciences sector increased in the first quarter of 2013 relative to the first quarter of 2012. The pharmaceutical segment recorded the largest gains in deal value during the quarter on the strength of several large transactions.

  • An HR perspective: Focusing on the future of healthcare benefits

    5/15/13 | Human resource services

    PwC recently convened several roundtables of employers in New York, Chicago, and Atlanta to discuss health coverage at this pivotal moment. This thought leadership article highlights the conversations and results of the related survey.

  • Webcast
    Why Unique Device Identification (UDI) and what lies ahead for the medtech industry? webcast – June 6, 2013

    5/14/13 | Pharmaceuticals & life science

    Please join us for a webcast featuring Jay Crowley from FDA and Jeffrey Secunda from AdvaMed as featured speakers. During this webcast, Jay and Jeffrey will provide their perspectives on the future of UDI in the medical device industry.

  • Webcast
    Proposed Regulations issued on compensation deduction limitation, how does this impact health insurance providers? – May 16, 2013

    5/1/13 | Human resource services

    Watch this one-hour webcast for a discussion on how the proposed regulations issued on compensation deduction limitation will impact health insurance providers.

  • Webcast
    Hot topics and technical updates impacting accounting and financial reporting webcast – May 2, 2013

    4/30/13 | Healthcare

    The next installment in PwC's Healthcare, Higher Education and Not-for-Profit quarterly webcast series provides updates on the various standard setting activities that have occurred since our January webcast. As always, the focus is on how those activities will affect not-for-profit organizations, with an emphasis on healthcare and higher education institutions.

  • Webcast
    New CHNA Requirements and Trends in Community Benefit Reporting webcast – May 23, 2013

    4/30/13 | Healthcare

    Please join PwC for a discussion regarding the recently issued proposed guidance affecting every tax-exempt hospital organization. This webcast will also review hospital facility’s community health needs assessment (CHNA) requirements and reporting obligations and will feature a broad range of PwC specialists.

  • 10Minutes
    10Minutes on investing in China's private healthcare system

    4/18/13 | Healthcare

    China recently introduced its 12th Five-Year Plan, which reinforces the government's commitment to easing ownership requirements. This 10Minutes discusses opportunities that private and foreign providers, payers, and investors can adopt to build a presence in China's growing healthcare market.

  • Scoring healthcare: Navigating customer experience ratings

    4/11/13 | Health Research Institute

    Healthcare companies have been gathering feedback from patients for years. Now, the accessibility of that feedback is influencing people’s healthcare decision making. Reporting requirements on ratings and reviews are prompting insurers and providers to look more comprehensively at the consumer experience.

  • IRS proposes regulations on compensation deduction limitation for health insurance providers

    4/5/13 | Human resource services

    The IRS has issued proposed regulations on the $500,000 compensation deduction limit for remuneration paid to employees, officers and directors of certain health insurance providers.

  • Medical device excise tax (updated March 28, 2013)

    3/29/13 | Pharmaceuticals & life science

    This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that medical device manufacturers will need to begin accounting for this tax for all sales, other than tax free sales, beginning January 1, 2013 and will need to consider the impact of this tax on their 2013 results.

  • Health Care Reform Roundup

    3/27/13 | Human resource services

    A slew of recent guidance from regulators about the Affordable Care Act (ACA) gives employers clarity about several provisions taking effect in 2014.

  • US healthcare M&A insights

    3/26/13 | Transaction services

    The US healthcare industry experienced a variety of transformative pressures in 2012. Find out more in this US healthcare M&A insights.

  • Webcast
    Alternative Investments: Insights on Managing Tax Risks and Protecting Your Institution webcast – March 19, 2013

    3/8/13 | Healthcare

    PwC discusses the tax reporting considerations that every tax-exempt organization investor should be aware when deciding to commit funds into the alternative investments market.

  • Webcast
    How to respond to the final omnibus HIPAA Rule: 10 things you need to know now webcast – February 28, 2013

    2/21/13 | Healthcare

    The new HIPAA changes will have immediate consequences. It is important for organizations to understand the financial and operational implications and develop a well thought out strategy to remain in compliance and support the new health information uses, health IT and channels.

  • New tax law extends research & development tax credit

    2/11/13 | Pharmaceuticals & life science

    This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that the new tax law extends research & development tax credit and provides guidance on accounting for the retroactive reinstatement of the R&D tax credit.

  • HR Innovation - Winter 2012/2013 - The opportunities and obstacles facing employers in a post-health reform world

    1/27/13 | Human resource services

    HR Innovation offers advanced thinking about the challenges that should be uppermost on the minds and agendas of organizations and their Human Resources (HR) leaders. In this issue of HR Innovation, we focus on HR Transaction Effectiveness, and delve into what it takes to effectively navigate the maze of critical talent-based decisions that can support deal success, shorten the time to close, and boost value.

  • Webcast
    Conflict minerals: What does Dodd-Frank Section 1502 mean for companies in the Life Sciences industry? – February 6, 2013

    1/25/13 | Pharmaceuticals & life science

    On August 22, 2012 the SEC issued a final rule on conflict minerals pursuant to Dodd-Frank Section 1502. Join us as PwC panelists from our Health Industries practice lead a discussion addressing the rule, what life sciences products are likely to be covered, and what companies should be doing now.

  • Top health industry issues of 2013

    1/10/13 | Health Research Institute

    PwC's Health Research Institute's annual report on issues impacting the health industries in the coming year.

  • Health reform re-elected: ACA implementation in tough fiscal times

    11/10/12 | Health Research Institute

    What will the impact of the US presidential election be on the cost of providing healthcare for your business? In our latest report, PwC's Health Research Institute provides a roadmap of the many changes headed your way, and offers a roadmap on how to sidestep any obstacles implementation may toss your way

  • IRS provides guidance needed by employers to comply with Affordable Care Act

    9/13/12 | Human resource services

    IRS recently released guidance that addresses some of the very technical details employers must deal with as they implement the Affordable Care Act (ACA).

  • Global Healthcare Deals Quarterly: Emerging markets grasp even greater share of healthcare M&A; Brazil is fertile ground for mHealth technology

    8/1/12 | Healthcare

    What are the recent investment trends and opportunities in global healthcare markets and what regions are likely to draw future merger and acquisition activity? Our 2Q 2012 edition focuses on the rapid pace of M&A activity in the key healthcare M&A emerging markets of Brazil and China.

  • Implications of the US Supreme Court ruling on healthcare

    7/2/12 | Health Research Institute

    This PricewaterhouseCoopers' Health Research Institute report comments on the implications of the US Supreme Court ruling on healthcare

  • Issues for employers following Supreme Court ACA decision

    7/2/12 | Human resource services

    A divided Supreme Court has ruled that the requirement under the Affordable Care Act (ACA) that all Americans have health insurance is a constitutional exercise of the Congress's power to tax.

  • Emerging mHealth: Paths for growth

    6/7/12 | Pharmaceuticals & life science

    PwC report shows developed and emerging markets see mHealth's potential to transform healthcare innovation, but resistance to change could be a barrier.

  • Global Healthcare Deals Quarterly: Invest in an evolving global hospital market

    5/31/12 | Healthcare

    What are the recent investment trends and opportunities in global healthcare markets and what regions are likely to draw future merger and acquisition activity? Our 1Q 2012 edition focuses on investments in the evolving global hospital sector. Global deals activity has gotten off to a slow start in 2012, with softer volumes and smaller deal sizes reflecting continued economic uncertainty in global markets.

  • Potential Accounting Implications of Supreme Court Decision on the Affordable Care Act

    5/31/12 | Pharmaceuticals & life science

    The Supreme Court heard arguments concerning the Affordable Care Act in March 2012 and expects to issue its decision on the constitutionality of the Affordable Care Act by the end of June 2012. If the law should be invalidated by the Supreme Court, either in whole or in part, there could be significant accounting and financial reporting implications. This PwC Pharmaceutical and Life Sciences Industry Alert focuses on the potential accounting implications of the Supreme Court decision on the Affordable Care Act.

  • Medical cost trend: Behind the numbers, 2013

    5/15/12 | Health Research Institute

    Healthcare spending in the United States is expected to grow at a historically low rate of 7.5 percent next year, according to the annual Behind the numbers report on medical cost trend, published by PwC Health Research Institute. More than half of the employers surveyed are considering increasing employees' share of health benefit cost and expanding health and wellness programs in 2013.

  • Greece Debt Restructuring

    4/9/12 | Pharmaceuticals & life science

    In February 2012, the Greek government announced a debt restructuring which required holders to exchange their two-year and three-year bonds, currently scheduled to mature in December 2012 and 2013, for new non-interest bearing government bonds with longer maturities and a reduced redemption value. This edition of PwC's Pharmaceutical and Life Sciences Industry Alert discusses why pharmaceutical companies will need to evaluate the debt restructuring in order to properly assess the accounting impact of this event.

  • Social media likes healthcare: From marketing to social business

    3/7/12 | Health Research Institute

    With one half of health industry executives saying they are concerned about how to integrate social media data into their business strategy there is a recognition social media presents a significant industry challenge.

  • Needles in a haystack: Seeking knowledge with clinical informatics

    2/29/12 | Health Research Institute

    Increasing importance of clinical informatics for healthcare payers, providers, and the pharmaceutical industries: PwC

  • Administration issues final rules on PPACA summary of benefits and coverage

    2/15/12 | Human resource services

    The Departments of Treasury, Labor and Health and Human Services have released final rules regarding the summary of benefits and coverage required to be provided by health insurance issuers and group health plans under the Patient Protection and Affordable Care Act ("PPACA"). For more, read this edition of HRS insight.

  • Medtech focus: IRS and Treasury publish notice of proposed rulemaking implementing new Medical Device Excise Tax

    2/8/12 | Health Research Institute

    IRS and Treasury publish notice of proposed rulemaking implementing new Medical Device Excise Tax, February 2012

  • Bridging the Gap: Meeting the challenges of healthcare development in South East Asia

    2/7/12 | Healthcare

    South East Asia’s evolving health systems are using healthcare public-private partnerships (PPPs) to expand capacity and quality of healthcare in emerging markets.

  • European Economic Environment - US GAAP Accounting Considerations

    1/11/12 | Pharmaceuticals & life science

    There continues to be significant economic problems in some European countries that are members of the single currency (the Euro zone) as well as potential uncertainty about the single currency itself. This Pharma and Life Sciences Alert discusses why austerity programs aimed at reducing debt levels in these countries have not eliminated the possibility that some European countries could default on sovereign debt and other governmental obligations.

  • Dataline
    Dataline (Supplement): Revenue from contracts with customers - Pharmaceutical and life sciences industry (No. 2011-35)

    12/1/11 | Assurance services

    The FASB and IASB released an updated exposure draft, Revenue from Contract with Customers, on November 14, 2011, and are requesting comments by March 13, 2012. In Dataline 2011-35, we share our analysis of and insight on the overall proposal. This industry supplement to Dataline 2011-35 provides specific examples and assessments of the potential affect of the updated proposal on the pharmaceutical and life sciences industry.

  • MoneyTree: High-dollar deals

    6/29/10 | Pharmaceuticals & life science

    Life sciences venture capital falls short of strong second-quarter performance, but year-over-year trend remains positive.